loading...| Preferred Name |
Tranylcypromine Sulfate |
|
| Synonyms |
(+-)-Trans-2-Phenylcyclopropylamine Sulfate (2:1) 1-Amino-2-phenylcyclopropane Sulfate Tranylcypromine Sulfate TRANYLCYPROMINE SULFATE Parnate |
|
| Definitions |
The sulfate salt form of tranylcypromine, an orally bioavailable, nonselective, irreversible, non-hydrazine inhibitor of both monoamine oxidase (MAO) and lysine-specific demethylase 1 (LSD1/BHC110), with antidepressant and anxiolytic activities, and potential antineoplastic activities. Upon oral administration, tranylcypromine exerts its antidepressant and anxiolytic effects through the inhibition of MAO, an enzyme that catalyzes the breakdown of the monoamine neurotransmitters serotonin, norepinephrine, epinephrine and dopamine. This increases the concentrations and activity of these neurotransmitters. Tranylcypromine exerts its antineoplastic effect through the inhibition of LSD1. Inhibition of LSD1 prevents the transcription of LSD1 target genes. LSD1, a flavin-dependent monoamine oxidoreductase and a histone demethylase, is upregulated in a variety of cancers and plays a key role in tumor cell proliferation, migration, and invasion. |
|
| ID |
http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C61980 |
|
| CAS_Registry |
13492-01-8 |
|
| CHEBI_ID |
CHEBI:9653 |
|
| Chemical_Formula |
2C9H11N.H2SO4 |
|
| code |
C61980 |
|
| Concept_In_Subset |
http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C176424 http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157711 http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157712 http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128784 |
|
| Contributing_Source |
FDA GDC |
|
| DEFINITION |
The sulfate salt form of tranylcypromine, an orally bioavailable, nonselective, irreversible, non-hydrazine inhibitor of both monoamine oxidase (MAO) and lysine-specific demethylase 1 (LSD1/BHC110), with antidepressant and anxiolytic activities, and potential antineoplastic activities. Upon oral administration, tranylcypromine exerts its antidepressant and anxiolytic effects through the inhibition of MAO, an enzyme that catalyzes the breakdown of the monoamine neurotransmitters serotonin, norepinephrine, epinephrine and dopamine. This increases the concentrations and activity of these neurotransmitters. Tranylcypromine exerts its antineoplastic effect through the inhibition of LSD1. Inhibition of LSD1 prevents the transcription of LSD1 target genes. LSD1, a flavin-dependent monoamine oxidoreductase and a histone demethylase, is upregulated in a variety of cancers and plays a key role in tumor cell proliferation, migration, and invasion. |
|
| FDA_UNII_Code |
7ZAT6ES870 |
|
| FULL_SYN |
(+-)-Trans-2-Phenylcyclopropylamine Sulfate (2:1) 1-Amino-2-phenylcyclopropane Sulfate Tranylcypromine Sulfate TRANYLCYPROMINE SULFATE Parnate |
|
| Has_Free_Acid_Or_Base_Form | ||
| Is_Value_For_GDC_Property | ||
| label |
Tranylcypromine Sulfate |
|
| Legacy Concept Name |
Tranylcypromine_Sulfate |
|
| Maps_To |
Tranylcypromine Sulfate |
|
| NCI_Drug_Dictionary_ID |
765903 |
|
| PDQ_Closed_Trial_Search_ID |
765903 |
|
| PDQ_Open_Trial_Search_ID |
765903 |
|
| Preferred_Name |
Tranylcypromine Sulfate |
|
| prefixIRI |
Thesaurus:C61980 |
|
| Semantic_Type |
Pharmacologic Substance |
|
| UMLS_CUI |
C0304369 |
|
| subClassOf |